title: Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule.
abstract: We compared the immunogenicity of two vaccination schedules with either a systemic or a mucosal booster, both following a mucosal primary vaccination with a recombinant outer membrane fusion protein of Pseudomonas aeruginosa (OprF-I) in 12 healthy volunteers. The systemic booster induced higher levels of OprF-I-specific serum antibodies of IgG isotype, with a mean+/-S.E.M. of 32.6+/-7.8x10(7) enzyme-linked immunosorbent assay (ELISA) units (EU) as compared to the nasal booster with 14.6+/-2.1x10(7) EU (P=0.05). Specific serum IgA antibodies and antibodies in saliva did not differ between the two vaccination groups. We conclude that a combined mucosal/systemic vaccination with the OprF-I vaccine may offer an enhanced systemic immunogenicity. Further studies on the long-term immunogenicity and induction of antibodies on the respiratory airway surface are warranted.
authors.affiliation: Paediatric Pulmonology and Neonatology, Hanover Medical School, 30623, Hanover, Germany.
authors.forename: Kerstin
authors.initials: K
authors.lastname: Göcke
authors.forename: Ulrich
authors.initials: U
authors.lastname: Baumann
authors.forename: Hartmut
authors.initials: H
authors.lastname: Hagemann
authors.forename: Josef
authors.initials: J
authors.lastname: Gabelsberger
authors.forename: Heinz
authors.initials: H
authors.lastname: Hahn
authors.forename: Joachim
authors.initials: J
authors.lastname: Freihorst
authors.forename: Bernd Ulrich
authors.initials: BU
authors.lastname: von Specht
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology*; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000097:blood; D008074:Lipoproteins / Q000235:genetics / Q000276:immunology*; D008571:Men; D018272:Porins / Q000235:genetics / Q000276:immunology*; D011552:Pseudomonas Infections / Q000276:immunology / Q000517:prevention & control; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D008074:Lipoproteins; D018272:Porins; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic; C060507:outer membrane lipoprotein I, Bacteria